General News

MALVERN, Pa. , May 21, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company presented a poster at the 2018 International Investigative Dermatology

MALVERN, Pa. , May 2, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM) (the Company), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces it has confidentially submitted a registration statement to the United States

MALVERN, Pa. , April 26, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company expects to release its results for the year ended December 31, 2017 on

MALVERN, Pa. , Feb. 27, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued notices of allowance

MALVERN, Pa. , Feb. 20, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announced today that Alex Martin , CEO, will be presenting at the RBC Capital Markets 2018 Global

Phase 2 Allergic Conjunctivitis Study Ahead of Schedule; Top-Line Results Anticipated by End of Q1 Phase 2 Atopic Dermatitis Study on Track with Top-Line Results Expected in Late Q3 Year-end 2017 Cash, Cash Equivalents and Short-term Investments Were $33.9 Million MALVERN, Pa. , Feb.

MALVERN, Pa., Jan. 2, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin, CEO, will be presenting at the 5 th Annual Dermatology Summit, an

MALVERN, Pa. , Dec. 12, 2017 /PRNewswire/ -- Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announces the first patient has been dosed in its Phase 2 study of PR013, the Company's topical

MALVERN, Pa., Dec. 5, 2017 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announced the first patient has been dosed in its Phase 2 study of PR022, the Company's proprietary

In Vivo and In Vitro Data Demonstrate Reduced Itch and Inflammation Progressing to Phase 2 trial in coming weeks MALVERN, Pa. , Nov. 21, 2017 /PRNewswire/ -- Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory